Jake R. Morgan, PhD
Research Assistant Professor
Boston University School of Public Health
Health Law, Policy & Management

PhD, Boston University
MS, Montana State University
BS, Hillsdale College



Jake Morgan, PhD, is a health services researcher specializing in using real-world data to inform evidence-based policy, update clinical guidelines, and improve patient access to and quality of care.

His work is focused on the opioid overdose epidemic and how to best support patients by promoting access and retention to medications for opioid use disorder. His work on the comparative effectiveness of medications for opioid use disorder has been cited in a call for research by the director of the National Institute on Drug Abuse Nora Volkow and he has a history of collaboration with Massachusetts Department of Public Health to evaluate and inform addiction treatment services. His work has consistently reinforced the importance of patient choice when it comes to treatment for opioid use disorder and has documented the effects of policies that usurp this choice through onerous requirements for treatment, restricting access to vulnerable populations such as individuals who are incarcerated, and cost-sharing schemes that disincentivize treatment. As an applied health economist with extensive experience in statistical, econometric, and simulation modeling approaches, Dr. Morgan frequently works alongside clinical researchers to highlight (and cost) the best treatment interventions for patients. He is currently involved with the Health Economics core of the The HEALing Communities Study; the Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND) study; the Researching Effective Strategies to Prevent Opioid Death (RESPOND) simulation model, and; The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for HCV trial.

Dr. Morgan works closely with The Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) as a member of the Population Data and Modeling Core and is the primary representative for Boston University School of Public Health. The Center’s mission is to develop and disseminate health economic research on healthcare utilization, health outcomes, and health-related behaviors to inform policy to improve care for individuals with substance use disorder, HIV, and HCV. To that end, CHERISH offers resources and consultations to support this type of research for trainees and investigators at any stage. Please see https://cherishresearch.org/ or contact Dr. Morgan to learn more.


Assessing and Addressing Inequities in Cardiovascular Health of Transgender and Gender Diverse Persons
07/01/2022 - 06/30/2025 (Subcontract PI)
Boston Medical Center Corporation Doris Duke Fdn


Health Economics of Substance Use Disorder, HCV, and HIV Treatment: Evaluating Intervention Outcomes for Individuals, Systems, and Communities
07/15/2020 - 04/30/2024 (Subcontract PI)
Weill Medical College of Cornell University NIH NIDA
5P30DA040500-09

Researching Effective Strategies to Prevent Opioid Death (RESPOND)
04/01/2019 - 03/31/2024 (Subcontract PI)
Boston Medical Center Corporation NIH NIDA
5R01DA046527-05

Prevention and Rescue Of Fentanyl and Other Opioid Overdoses Using Optimized Naloxone Distribution Strategies (PROFOUND)
05/15/2019 - 02/29/2024 (Subcontract PI)
Weill Medical College of Cornell NIH NIDA
5U01DA047408-05

IMPROVING NALOXONE ACCESS AND ITS EFFECTS ON DRUG ABUSE AND OVERDOSES
02/25/2019 - 08/31/2023 (Subcontract PI)
RAND Corporation HHS CDC
5R01CE002999-02

Evaluation of a persuasive health communication intervention designed to increase HIV/HCV screening
09/30/2022 - 07/31/2023 (Subcontract PI)
Icahn School of Medicine at Mount Sinai NIH NIDA
1R01DA055533-01

The Determining Effective Testing in Emergency Departments and Care Coordination on Treatment Outcomes (DETECT) for HCV Trial
01/01/2019 - 12/31/2022 (Subcontract PI)
Denver Health Medical Center NIH NIDA
5R01DA042982-05

Expanding FDA's Opioids Systems Model to Enable Economic Evaluations and Outcome Analyses of National Opioid Policies
09/01/2020 - 08/31/2022 (Subcontract PI)
The General Hospital Corporation d/b/a Massachusetts General Hospital HHS FDA
1U01FD007064-01

Utilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorder
05/01/2021 - 04/30/2022 (Subcontract PI)
Weill Medical College of Cornell NIH NIDA
3P30DA040500-07S1

Impact of health insurance type and transitions on treatment for opioid use disorder
04/01/2019 - 03/31/2022 (Subcontract PI)
Boston Medical Center Corporation Robert Wood Johnson


Showing 10 of 14 results. Show All Results


Title


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Morgan JR, Leech AA. Commentary on Schmidt et al.: Informed patient preference and prioritizing access to medications for opioid use disorder for pregnant individuals. Addiction. 2024 Apr 03. PMID: 38570825
     
  2. McCann NC, LaRochelle MR, Morgan JR. Out-of-pocket spending and health care utilization associated with initiation of different medications for opioid use disorder: Findings from a national commercially insured cohort. J Subst Use Addict Treat. 2024 Apr; 159:209281.View Related Profiles. PMID: 38122988
     
  3. Morgan JR, Assoumou SA. The limits of innovation: Directly addressing known challenges is necessary to improve the real-world experience of novel medications for opioid use disorder. Acad Emerg Med. 2023 Dec; 30(12):1285-1287.View Related Profiles. PMID: 37793818; PMCID: PMC10841521; DOI: 10.1111/acem.14814;
     
  4. Park TW, Baul TD, Morgan JR, Wilens TE, Yule AM. Trends in Attention-Deficit Hyperactivity Disorder Diagnosis and Pharmacotherapy Among Adults With Opioid Use Disorder. Psychiatr Serv. 2024 Mar 01; 75(3):214-220.View Related Profiles. PMID: 37789727
     
  5. Tin Y, Castry M, Bowers-Sword R, Shantharam S, Aldridge A, Zarkin GA, Starbird L, Linas BP, Barocas JA, Morgan JR. Establishing a Protocol for Determining the Costs of an Integrated Set of Evidence-based Practices Aimed at Reducing Opioid Overdose Deaths. J Addict Med. 2024 Jan-Feb 01; 18(1):13-18.View Related Profiles. PMID: 37768777; PMCID: PMC10872250; DOI: 10.1097/ADM.0000000000001218;
     
  6. Flam-Ross JM, Marsh E, Weitz M, Savinkina A, Schackman BR, Wang J, Madushani RWMA, Morgan JR, Barocas JA, Walley AY, Chrysanthopoulou SA, Linas BP, Assoumou SA. Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder. JAMA Netw Open. 2023 Sep 05; 6(9):e2329583.View Related Profiles. PMID: 37703018; PMCID: PMC10500382; DOI: 10.1001/jamanetworkopen.2023.29583;
     
  7. Leech AA, McNeer E, Roberts AW, Dusetzina SB, Lai P, Morgan JR, Patrick SW. Buprenorphine Out-of-Pocket Costs and Discontinuation in Privately Insured Adults With Opioid Use Disorder. JAMA Intern Med. 2023 Sep 01; 183(9):1023-1026. PMID: 37548972; PMCID: PMC10407758; DOI: 10.1001/jamainternmed.2023.2826;
     
  8. Zang X, Walley AY, Chatterjee A, Kimmel SD, Morgan JR, Murphy SM, Linas BP, Nolen S, Reilly B, Urquhart C, Schackman BR, Marshall BDL. Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: An interrupted time-series analysis in Massachusetts, USA. Addiction. 2023 Dec; 118(12):2413-2423.View Related Profiles. PMID: 37640687; DOI: 10.1111/add.16324;
     
  9. Chatterjee A, Yan S, Lambert A, Morgan JR, Green TC, Jeng PJ, Jalali A, Xuan Z, Krieger M, Marshall BDL, Walley AY, Murphy SM. Comparison of a national commercial pharmacy naloxone data source to state and city pharmacy naloxone data sources-Rhode Island, Massachusetts, and New York City, 2013-2019. Health Serv Res. 2023 Oct; 58(5):1141-1150.View Related Profiles. PMID: 37408299; PMCID: PMC10480090; DOI: 10.1111/1475-6773.14200;
     
  10. Kajtezovic S, Morgan JR, Fiascone S, Brandt HM, Perkins RB. Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series. Hum Vaccin Immunother. 2023 Dec 31; 19(1):2175541.View Related Profiles. PMID: 36798049; PMCID: PMC10026864; DOI: 10.1080/21645515.2023.2175541;
     
Showing 10 of 65 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 65 publications over 11 distinct years, with a maximum of 13 publications in 2022

YearPublications
20141
20156
20164
20173
20185
20196
20206
202110
202213
202310
20241


Families hit with high costs, waitlists for youth rehab in Oregon and nationwide

OPB 1/8/2024

Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study.

Physician's Weekly 11/9/2020

2016 Patient-Centered Outcomes Research Institute (PCORI): Trainee Scholarship
2015 Lee Lusted Prize winner
Contact for Mentoring:

617.358.2960
Download vCard

Morgan's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
See all (211) concept(s)
_
Media Mentions
_
Co-Authors
See all (39) people
_
Similar People
See all (60) people
_
Same Department
Search Department